This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone deacetylase abexinostat in combination with pazopanib to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results